| # | Title | Journal | Year | Citations |
|---|
| 1 | Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten‐free diet | GastroHep | 2020 | 43 |
| 2 | Latiglutenase treatment for celiac disease: symptom and quality of life improvement for seropositive patients on a gluten‐free diet | GastroHep | 2019 | 24 |
| 3 | Paediatric onset inflammatory bowel disease is a distinct and aggressive phenotype—a comparative population‐based study | GastroHep | 2019 | 20 |
| 4 | The effects of COVID‐19 on IBD prescribing and service provision in a UK tertiary centre | GastroHep | 2020 | 14 |
| 5 | Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients | GastroHep | 2019 | 12 |
| 6 | Resistance patterns of refractory Helicobacter pylori infection in a referral centre in the Delaware Valley | GastroHep | 2020 | 12 |
| 7 | Liver injury, SARS‐COV‐2 infection and COVID‐19: What physicians should really know? | GastroHep | 2021 | 11 |
| 8 | Impact of COVID‐19 pandemic on surveillance of hepatocellular carcinoma: A study in patients with chronic hepatitis C after sustained virologic response | GastroHep | 2020 | 10 |
| 9 | Prevention of paracentesis‐induced circulatory dysfunction—A systematic review and network meta‐analysis | GastroHep | 2020 | 10 |
| 10 | Probable neuropsychiatric toxicity of polyethylene glycol: roles of media, internet and the caregivers | GastroHep | 2019 | 9 |
| 11 | Patterns and motivations of Cannabis use amongst patients with inflammatory bowel disease | GastroHep | 2019 | 8 |
| 12 | Liver‐specific scores as predictors of mortality in spontaneous bacterial peritonitis | GastroHep | 2020 | 8 |
| 13 | Changes in hepatic fibrosis stages after achieving SVR following direct‐acting anti‐viral treatment: a prospective study | GastroHep | 2020 | 8 |
| 14 | Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response | GastroHep | 2021 | 8 |
| 15 | Circulating bile acid profiles in Japanese patients with NASH | GastroHep | 2019 | 7 |
| 16 | Hypophosphataemia after intravenous iron therapy with ferric carboxymaltose—Real world experience from a tertiary centre in the UK | GastroHep | 2020 | 7 |
| 17 | The association of Helicobacter pylori with pancreatic cancer | GastroHep | 2020 | 7 |
| 18 | Predicting mortality for hepatorenal syndrome with liver‐specific scores | GastroHep | 2020 | 7 |
| 19 | SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease | GastroHep | 2021 | 7 |
| 20 | Clinical characteristics and outcomes of mild to moderate alcoholic hepatitis | GastroHep | 2019 | 6 |
| 21 | Proton pump inhibitors are not associated with an increased risk of colorectal cancer | GastroHep | 2020 | 6 |
| 22 | Comparison of Risk Scoring Systems in Hospitalised Patients who Develop Upper Gastrointestinal Bleeding | GastroHep | 2021 | 6 |
| 23 | Lenvatinib for unresectable hepatocellular carcinoma: the first Indian experience | GastroHep | 2021 | 6 |
| 24 | Management of patients with chronic hepatitis C failing repeated courses of interferon‐free direct acting antiviral combination therapy | GastroHep | 2019 | 5 |
| 25 | Cost‐effectiveness of integrating gut microbiota analysis into hospitalisation prediction in cirrhosis | GastroHep | 2020 | 5 |
| 26 | Predicting mortality for cirrhotic patients with acute oesophageal variceal haemorrhage using liver‐specific scores | GastroHep | 2021 | 5 |
| 27 | The clinical and economic burden of patients with chronic liver disease and thrombocytopaenia receiving platelet transfusions during planned invasive procedures | GastroHep | 2019 | 4 |
| 28 | A narrative review of factors associated with the development and progression if non‐alcoholic fatty liver disease | GastroHep | 2019 | 4 |
| 29 | The effects of proactive therapeutic drug monitoring vs reactive therapeutic drug monitoring in a virtual biologic clinic, a retrospective cohort study | GastroHep | 2019 | 4 |
| 30 | Helicobacter pyloriinfection is strongly associated with metabolic syndrome, and weakly associated with non‐alcoholic fatty liver disease, in a US Hispanic population | GastroHep | 2019 | 4 |
| 31 | Assessing efficacy of hepatocellular carcinoma prediction scores to prioritise hepatitis B surveillance in the COVID‐19 era | GastroHep | 2021 | 4 |
| 32 | Cancer incidence and factors associated with malignancies in coeliac disease during long‐term follow‐up | GastroHep | 2021 | 4 |
| 33 | Best Practices in Liver Biopsy Histologic Assessment for Nonalcoholic Steatohepatitis Clinical Trials: Expert Opinion | GastroHep | 2022 | 4 |
| 34 | Assessing spleen stiffness by point shear‐wave elastography: Is it feasible and reproducible in patients with chronic liver disease? Is it useful to predict portal hypertension? | GastroHep | 2019 | 3 |
| 35 | Letter: development of biliary/renal stone and sludge after Ceftriaxone intake is associated with aberrant UDP‐Glucuronosyltransferase activity (ie Gilbert’s syndrome) | GastroHep | 2019 | 3 |
| 36 | Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease | GastroHep | 2019 | 3 |
| 37 | De‐escalating medical therapy in Crohn’s disease patients who are in deep remission: A RAND appropriateness panel | GastroHep | 2019 | 3 |
| 38 | External validation of an algorithm combining multi‐analyte blood tests (FibroTest‐LCR1‐LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease | GastroHep | 2019 | 3 |
| 39 | The relationship between previous antimicrobial use, antimicrobial resistance and treatment outcome among Alaskans treated forHelicobacter pyloriinfection | GastroHep | 2019 | 3 |
| 40 | Development of biliary and renal stone and sludge after taking Ceftriaxone is associated with a defect in UDP‐Glucuronosyltransferase (ie Gilbert’s syndrome) | GastroHep | 2019 | 3 |
| 41 | A novel distinctive form of identification for differential diagnosis of irritable bowel syndrome, inflammatory bowel disease, and healthy controls | GastroHep | 2020 | 3 |
| 42 | Double‐blind, randomised, placebo‐controlled crossover trial to evaluate the clinical efficacy of rifaximin in patients with moderate to severe active Crohn’s disease | GastroHep | 2020 | 3 |
| 43 | Rifamycin vs placebo for the treatment of acute uncomplicated diverticulitis: A randomised, double‐blind study | GastroHep | 2020 | 3 |
| 44 | Implementation of an intervention bundle leads to quality improvement in ulcerative colitis endoscopy reporting | GastroHep | 2020 | 3 |
| 45 | Obeticholic acid for treatment of NAFLD—A drug in search of a disease | GastroHep | 2020 | 3 |
| 46 | Prognostic risk score for gastrointestinal bleeding: Which one is best? | GastroHep | 2021 | 3 |
| 47 | Mortality in patients hospitalised for diverticulitis in Sweden—A national population‐based cohort study | GastroHep | 2021 | 3 |
| 48 | Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with direct‐acting antivirals | GastroHep | 2021 | 3 |
| 49 | Dried blood spot‐based detection of serological profiles of hepatitis B and C infections and their prevalence in Cambodia | GastroHep | 2021 | 3 |
| 50 | Profiling the Use of Complementary Alternative Medicines among Inflammatory Bowel Disease Patients: Results from a Single Center Survey | GastroHep | 2022 | 3 |
